Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)
Autore:
Rinaldi, D; Lormand, N; Brierre, J; Cole, J; Barnes, B; Fontenot, F; Buller, E; Rainey, J;
Indirizzi:
Louisiana Oncol Associates, Lafayette, LA 70506 USA Louisiana Oncol Associates Lafayette LA USA 70506 Lafayette, LA 70506 USA
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 5, volume: 19, anno: 2001,
pagine: 467 - 474
SICI:
0735-7907(2001)19:5<467:APITOT>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
2ND-LINE TREATMENT;
Keywords:
gemcitabine; non-small cell lung cancer; topotecan;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Rinaldi, D Louisiana Oncol Associates, 501 W St Mary Blvd,Suite 200, Lafayette, LA 70506 USA Louisiana Oncol Associates 501 W St Mary Blvd,Suite 200 Lafayette LA USA 70506
Citazione:
D. Rinaldi et al., "A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)", CANCER INV, 19(5), 2001, pp. 467-474

Abstract

The purposes of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activityof topotecan (TOP) and gemcitabine (GEM) combination therapy when administered to patients with previously treated advanced, non-small cell lung cancel Both compounds were administered intravenously over 30 min, with TOP on days 1-5 and GEM on days 1 and 5 only. Nineteen patients were treated with 75 courses at three dose levels. The MTD was 0.75 and 400 mg/m(2) for TOP and GEM, respectively, with thrombocytopenia and neutropenin as the DLTs. Partial responses were achieved in 3 of 17 patients (18%) with measurable disease. Six patients (32%) had disease stabilization for at least four courses of treatment. The median survival was 10 months from the initiation of TOP and GEM. This combination was relatively well tolerated and exhibited promising antitumour. activity in patients with advanced previously treated, non-small cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 18:58:29